Modified ATT Regimen in Metabolic Acidosis
When pyrazinamide must be omitted due to metabolic acidosis, use rifampicin and isoniazid for 9 months, supplemented with ethambutol for the initial 2 months 1.
Rationale for Pyrazinamide Exclusion
Pyrazinamide is contraindicated in metabolic acidosis because it functions as a weak acid prodrug that requires acidic pH for conversion to its active form (pyrazinoic acid) and can further acidify the intracellular environment 2. In patients with pre-existing metabolic acidosis, pyrazinamide may worsen the acid-base disturbance and increase toxicity risk.
Recommended Modified Regimen
Standard 9-Month Regimen (Drug-Susceptible TB)
Intensive Phase (2 months):
- Rifampicin: 10 mg/kg daily (max 600 mg if >50 kg, 450 mg if <50 kg)
- Isoniazid: 5 mg/kg daily (max 300 mg)
- Ethambutol: 15 mg/kg daily
Continuation Phase (7 months):
- Rifampicin: 10 mg/kg daily
- Isoniazid: 5 mg/kg daily
Dosing Considerations
- Pyridoxine supplementation: 25-50 mg daily with isoniazid to prevent peripheral neuropathy, especially important in patients with metabolic derangements 3
- Ethambutol monitoring: Check visual acuity and color vision monthly due to risk of optic neuritis at 15 mg/kg dosing 1
- The 15 mg/kg dose of ethambutol carries minimal ocular toxicity risk and is preferred over 25 mg/kg 1
Alternative Scenarios
If Isoniazid Resistance is Documented
Use rifampicin and ethambutol for 12 months, with pyrazinamide for the first 2 months only if metabolic acidosis has resolved 1. If pyrazinamide remains contraindicated, extend rifampicin-ethambutol to 18 months 1.
If Rifampicin Resistance is Present
This requires an 18-month regimen with isoniazid, ethambutol, and a fluoroquinolone (levofloxacin or moxifloxacin), avoiding pyrazinamide 1, 4. Refer to specialized MDR-TB centers for management 1.
Critical Monitoring Requirements
Liver Function Surveillance
Even without pyrazinamide, monitor liver enzymes because rifampicin can enhance isoniazid hepatotoxicity 5:
- First 2 weeks: Check AST/ALT twice weekly
- Weeks 2-8: Check every 2 weeks
- After 2 months: Monthly monitoring
Stop all drugs if:
- AST/ALT rises to >5× upper limit of normal, OR
- Bilirubin rises with any transaminase elevation 1
Acid-Base Status
Monitor serum bicarbonate and pH periodically to ensure metabolic acidosis is improving, as this may allow future consideration of standard 6-month regimens if acidosis resolves early in treatment.
Important Caveats
Do not attempt to shorten treatment duration below 9 months when pyrazinamide is omitted—this is the minimum effective duration supported by clinical trials 1. The 6-month short-course regimen is only effective when pyrazinamide is included for the first 2 months.
Directly observed therapy (DOT) is strongly recommended for the 9-month regimen to ensure adherence, as treatment failure or relapse rates increase with longer regimens 3.
Address the underlying cause of metabolic acidosis concurrently, as uncontrolled acidosis may impair drug absorption and immune function, potentially compromising TB treatment outcomes 6, 7.